Search results for "primary vaccination"

showing 2 items of 2 documents

Detection of delayed vaccinations: a new approach to visualize vaccine uptake

2002

For the prevention of pertussis and invasive Haemophilus influenzae type b (Hib) infections, each with a peak for mortality and serious complications in the first year of life, early vaccination is important and needs adequate monitoring. In a 1999 national coverage survey the timing of uptake of these vaccines in German children was therefore assessed conventionally at defined age thresholds and with a new adaptation of the Kaplan–Meier (KM) method estimating immunization uptake over time by 1 minus the survival function s(t). Only 6% and 9% of children were vaccinated against pertussis and Hib in accordance with the national recommended primary vaccination schedule. Coverage levels for th…

MaleBordetella pertussisPediatricsmedicine.medical_specialtyHaemophilus InfectionsTime FactorsWhooping CoughEpidemiologyHaemophilus influenzae typePrimary vaccinationFirst year of lifemedicine.disease_causeHaemophilus influenzaeGermanymedicineHumansImmunization ScheduleWhooping coughHaemophilus VaccinesPertussis VaccinebiologyImmunization Programsbusiness.industryInfant NewbornInfantmedicine.diseasebiology.organism_classificationHealth SurveysVaccinationInfectious DiseasesImmunizationPopulation SurveillanceImmunologyFemalebusinessResearch ArticleEpidemiology and Infection
researchProduct

Combined hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Hemophilus influenzae type b vaccine; Infanrix™ hexa: T…

2014

Infant vaccination using 2-dose priming at 3 and 5 mo of age with a booster at 11–12 mo of age was pioneered in Italy. The 3-5-11 schedule is now used in a growing number of European countries. Infanrix™ hexa (DTPa-HBV-IPV/Hib, GlaxoSmithKline Vaccines) was first licensed for use in 2000 and has been the only pediatric hexavalent vaccine available since 2005. We reviewed available clinical trial data describing the immunogenicity of DTPa-HBV-IPV/Hib when administered at 3, 5, and 11 mo of age, and conducted an analysis of safety using global and Italian post-marketing surveillance data. In Italy, DTPa-HBV-IPV/Hib has a demonstrated safety record extending over a decade of use, it has been a…

safetybooster vaccination; combination vaccines; hexavalent vaccine; immunogenicity; Italy; primary vaccination; safety; Clinical Trials as Topic; Diphtheria-Tetanus-Pertussis Vaccine; Haemophilus Vaccines; Hepatitis B Vaccines; Humans; Italy; Poliovirus Vaccine Inactivated; Product Surveillance Postmarketing; Vaccination; Vaccines Combined; Medicine (all)Settore MED/42 - Igiene Generale e ApplicataImmunologySocio-culturaleReviewimmunogenicitySettore MED/42 - Igiene Generale E Applicatamedicine.disease_causeprimary vaccinationProduct Surveillance PostmarketingmedicineImmunology and AllergyHumansHepatitis B VaccinesVaccines CombinedDiphtheria-Tetanus-Pertussis VaccineHaemophilus VaccinesPharmacologycombination vaccinesbooster vaccination; combination vaccines; hexavalent vaccine; immunogenicity; Italy; primary vaccination; safety; Medicine (all)Clinical Trials as TopicVaccinescombination vaccineTetanusbusiness.industryCombinedImmunogenicityPoliovirusDiphtheriaMedicine (all)VaccinationInactivatedHepatitis Bmedicine.diseaseVirologyProduct SurveillancePostmarketingClinical trialVaccinationPoliovirus Vaccinebooster vaccinationPoliovirus Vaccine InactivatedInfanrix hexaItalyhexavalent vaccine; primary vaccination; booster vaccination; Italy; combination vaccines; immunogenicity; safetybusinesshexavalent vaccine
researchProduct